Hervé Hoppenot
Director

Hervé Hoppenot serves on the Boards of Directors of Pierre Fabre Laboratories, N-Power Medicine, and as chairman of the Board of Directors for Maze Therapeutics. Previously, Mr. Hoppenot was an advisor to the CEO and served on the Board of Directors of Incyte, after serving 11 years as the company’s chairman and CEO. Under his leadership, Incyte tripled the number of clinical candidates, established an international presence in 15 countries and grew revenues from $350 million to $4.2 billion. Previously, Mr. Hoppenot served as president of Novartis Oncology, originally joining as chief commercial officer, overseeing the industry’s largest oncology pipeline. Mr. Hoppenot started his career at Rhône Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including as vice president of oncology and head of the U.S. oncology business unit. He holds a degree from ESSEC Business School in France.